A functional and structural basis for TCR cross-reactivity in multiple sclerosis

By Heather Lang, Helle Jacobsen, S. Ikemizu, Christina Andersson, K. Harlos, L. Madsen, P. Hjorth, L. Søndergaard, A. Svejgaard, K. Wucherpfennig and 4 more. Nature Immunology, 2002

596 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/787e57ac667af2c0a8399694de66af0c294d4ec3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Ragul Gowthaman
2. Brian G. Pierce

In Molecular Biology

1. Ragul Gowthaman
2. Brian G. Pierce
3. J. Rossjohn

Citations in the corpus

• Mechanisms Underlying Inflammation in Neurodegeneration (2010, unknown): “Other common pathogens, such as Epstein-Barr virus and some enterobacteria, have also been associated with the onset of MS (Lang et al., 2002), although the critical antigens have not been defined.”
• HLA variation and disease (2018, background): “…mechanisms may act to trigger multiple sclerosis, a patient­derived TCR has been identified that recognizes both HLA­DRB1*15:01­restricted MBP and an EBV peptide presented by HLA­DRB5*01:01 (TABLE 1) , which is encoded by an allele in high linkage disequilibrium with the HLA‑DRB1*15:01 allele 32 .”
• The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. (2006, background): “These pathogens acquired sufficient homology to engage myelin-specific T cells and drive a misguided response (Lang et al., 2002).”
• Multiple sclerosis – a review (2018, background): “Evidence regarding the mechanism via which EBV increases MS risk is heterogeneous; molecular mimicry is historically a popular theory [15].”
• TCRmodel: high resolution modeling of T cell receptors from sequence (2018, background): “…immune clearance of viruses and pathogens, while TCR autoreac-tivity is associated with a range of autoimmune diseases including diabetes (1) and multiple sclerosis (2), and studies have demonstrated that TCRs have major potential as cell-based (3,4) and soluble therapeutics (5) for cancer.”